Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) vs. EU-Perjeta® Along with Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients with Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer. This evidence concerns the gene ERBB2 and breast carcinoma.